Price Alert

C4 Therapeutics Inc. (CCCC)

NASDAQ: CCCC · Real-Time Price · USD

2.27

0.06 (2.71%)

At close: Oct 03, 2025, 3:59 PM

2.27

0.00%

After-hours: Oct 03, 2025, 07:37 PM EDT

2.71% (1D)

Bid	1.66
Market Cap	161.56M
Revenue (ttm)	34.24M
Net Income (ttm)	-111.58M
EPS (ttm)	-1.59
PE Ratio (ttm)	-1.43
Forward PE	-1.26
Analyst	Buy
Dividends	n/a

Ask	2.84
Volume	1,631,425
Avg. Volume (20D)	1,826,623
Open	2.22
Previous Close	2.21
Day's Range	2.22 - 2.33
52-Week Range	1.08 - 7.14
Beta	2.96
Ex-Dividend Date	n/a

About CCCC

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CCCC

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CCCC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

C4 Therapeutics Inc. is scheduled to release its earnings on Oct 30, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 weeks ago

+34.21%

C4 Therapeutics shares are trading higher after St... Unlock content with Pro Subscription

1 month ago

+31.63%

C4 Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.

News

1 week ago · seekingalpha.com

C4 Therapeutics, Inc. - Special Call

C4 Therapeutics, Inc. - Special Call Company Participants Courtney Solberg - Senior Manager of Investor Relations Andrew Hirsch - CEO, President & Director Leonard M. J. Reyno - Chief Medical Officer ...

1 month ago · zacks.com

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Misses Revenue Estimates

C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.26 per share a year ago.